Added to YB: 2023-06-25
Pitch date: 2023-06-25
CRL [bullish]
Charles River Laboratories International, Inc.
Author Info
No bio for this author
Company Info
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.
Market Cap
$13.4B
Pitch Price
N/A
Price Target
400.00
Dividend
N/A
EV/EBITDA
16.99
P/E
-57.37
EV/Sales
4.07
Sector
Life Sciences Tools and Services
Category
value
Charles River Laboratories: A Great Compounder With Secular Tailwinds At A 10-Year Low Valuation
CRL: De facto monopoly on FDA drug approvals (supports 85% of 2020-22 approvals) at 10-yr low 21x P/E, <13x EV/EBITDA vs historical mid-20s-30s. 13% rev/17% EPS 10yr CAGR; bioprocessing tailwind (14%/yr into 2030s). EPS $10.38→$13.85 by '25. 30x mult=$300+ '23/$400 '25. Sold off on COVID rev roll-off & DoJ monkey-sourcing subpoena (14% drop)—both transient. Buy below $250.
Read full article (7 min)